A Clinical-molecular Prognostic Model To Predict Survival In Patients With Post Polycythemia Vera And Post Essential Thrombocythemia Myelofibrosis
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
Passamonti F, Maffioli M . Update from the latest WHO classification of MPNs: a user's manual. Hematol Am Soc Hematol Educ Program 2016; 2016: 534–542.
Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437–438.
Passamonti F, Rumi E, Arcaini L, Castagnola C, Lunghi M, Bernasconi P et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005; 104: 1032–1036.
Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008; 111: 3383–3387.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.
Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 2014; 99: e55–e57.
Gowin K, Coakley M, Kosiorek H, Mesa R . Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/ essential thrombocytosis myelofibrosis. Haematologica 2016; 101: e405–e406.
Chen M, Xu ZF, Xu JQ, Li B, Zhang PH, Qin TJ et al. Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Zhonghua Xue Ye Xue Za Zhi 2016; 37: 876–880.
Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861–1869.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472–1477.
Wassie E, Finke C, Gangat N, Lasho TL, Pardanani A, Hanson CA et al. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. Br J Haematol 2015; 169: 71–76.
Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062–1069.
Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K et al. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica 2017; 102: 79–84.
Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M et al. Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia 2016.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M et al. How to develop a more accurate risk prediction model when there are few events. BMJ 2015; 351: h3868.
Friedman J, Hastie T, Tibshirani R . Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010; 33: 1–22.
Grambsch PM, Therneau TM . Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.
Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F et al. Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. Am J Hematol 2016; 91: 681–686.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770.
Mesa RA, Passamonti F . Individualizing care for patients with myeloproliferative neoplasms: integrating genetics, evolving therapies, and patient-specific disease burden. Am Soc Clin Oncol Educ Book 2016; 35: e324–e335.
Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014; 123: 1833–1835.
Barosi G, Zhang MJ, Peter Gale R . Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? Leukemia 2014; 28: 2267–2270.
Passamonti F, Vannucchi AM, Cervantes F, Harrison C, Morra E, Kantarjian H et al. Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia 2015; 29: 739–740.
Cervantes F, Pereira A . Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 2017; 129: 832–837.
Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 2015; 125: 3347–3350.
Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013; 27: 1322–1327.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787–798.
Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 2015; 1: 643–651.
Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia 2017; 31: 896–902.
Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhauser M et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012; 157: 75–85.
Marty C, Lacout C, Droin N, Le Couedic JP, Ribrag V, Solary E et al. A role for reactive oxygen species in JAK2(V617F) myeloproliferative neoplasm progression. Leukemia 2013; 27: 2187–2195.
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. New Engl J Med 2014; 371: 2488–2498.
Vainchenker W, Constantinescu SN, Plo I . Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Res 2016; 5: F1000.
2023 To 2029 Essential Thrombocythemia Drug Market Report By Product Type & End Users
The MarketWatch News Department was not involved in the creation of this content.
Mar 28, 2023 (The Expresswire) -- Absolutereports.Com has conducted research titled "Essential Thrombocythemia Drug Market" for the years 2023 to 2029, which presents a detailed analysis of market dynamics and trends that will shape the future of the industry. The report offers insights into the competitive landscape, market drivers, challenges, and opportunities, along with key growth factors that will drive market expansion in the forecast period. The report has segmented the global Essential Thrombocythemia Drug market based on Type (Givinostat, Idasanutlin, Pracinostat, Ruxolitinib Phosphate, Others) and Application (Research Center, Hospital, Clinic, Others), with the Essential Thrombocythemia Drug market expected to lead during the forecast period of 2023.
Get a Sample PDF of the Report - https://www.Absolutereports.Com/enquiry/request-sample/22806938
Furthermore, the report presents a holistic view of the market by analyzing various factors such as technological advancements, regulatory policies, and macroeconomic factors that will impact the growth trajectory of the Essential Thrombocythemia Drug market. The report also includes a detailed analysis of the market segmentation by types, which highlights the key areas of growth and the potential opportunities for market players.
In addition, the report provides insights into the competitive landscape of the market, including the key players operating in the industry and their financial performance, product offerings, and business strategies. The report also includes a SWOT analysis of the market players, which provides an in-depth understanding of their strengths, weaknesses, opportunities, and barriers.
Get a Sample Copy of the Essential Thrombocythemia Drug Market Report 2023
Essential Thrombocythemia Drug Market Segment by Manufacturers, this report covers:
● AbbVie Inc ● Aop Orphan Pharmaceuticals AG ● F. Hoffmann-La Roche Ltd ● Galena Biopharma Inc ● Incyte Corp ● Italfarmaco SpA ● MEI Pharma Inc ● PharmaEssentia CorpOverall, Essential Thrombocythemia Drug Market research is a valuable resource for industry participants, investors, and other stakeholders looking to gain a deeper understanding of the market dynamics, growth potential, and competitive landscape of the Essential Thrombocythemia Drug market.
As the global economy mends, the growth of Essential Thrombocythemia Drug will have significant change from previous year. The global Essential Thrombocythemia Drug market size will reach significant USD in 2028, growing at a CAGR over the analysis period.
The Essential Thrombocythemia Drug Market report also splits the market by region: Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Middle East and Africa, Egypt, South Africa, Israel, Turkey, GCC Countries.
Inquire or Share Your Questions If Any before the Purchasing This Report - https://www.Absolutereports.Com/enquiry/pre-order-enquiry/22806938
Segmentation by type: breakdown data from 2017 to 2023
● Givinostat ● Idasanutlin ● Pracinostat ● Ruxolitinib Phosphate ● OthersSegmentation by application: breakdown data from 2017 to 2023
● Research Center ● Hospital ● Clinic ● OthersThe global Essential Thrombocythemia Drug market size is projected to grow from USD million in 2022 to USD million in 2029; it is expected to grow at a CAGR of Percent from 2023 to 2029.
United States market for Essential Thrombocythemia Drug is estimated to increase from USD million in 2022 to USD million by 2029, at a CAGR of Percent from 2023 through 2029.
China market for Essential Thrombocythemia Drug is estimated to increase from USD million in 2022 to USD million by 2029, at a CAGR of Percent from 2023 through 2029.
Europe market for Essential Thrombocythemia Drug is estimated to increase from USD million in 2022 to USD million by 2029, at a CAGR of Percent from 2023 through 2029.
Key Reasons to Purchase:
● To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape. ● Assess the production processes, major issues, and solutions to mitigate the development risk. ● To understand the most affecting driving and restraining forces in the Essential Thrombocythemia Drug market and its impact in the global market. ● Learn about the market strategies that are being adopted by leading respective organizations. ● To understand the outlook and prospects for the market.Purchase this Report (Price 3660 USD for a Single-User License) -https://www.Absolutereports.Com/purchase/22806938
Detailed TOC of Global Essential Thrombocythemia Drug Market Growth 2023-2029
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Essential Thrombocythemia Drug Annual Sales 2018-2029
2.2 Essential Thrombocythemia Drug Segment by Type
2.3 Essential Thrombocythemia Drug Sales by Type
2.4 Essential Thrombocythemia Drug Segment by Channel
2.5 Essential Thrombocythemia Drug Sales by Channel
3 Global Essential Thrombocythemia Drug by Company
3.1 Global Essential Thrombocythemia Drug Breakdown Data by Company
3.2 Global Essential Thrombocythemia Drug Annual Revenue by Company (2018-2023)
3.3 Global Essential Thrombocythemia Drug Sale Price by Company
3.4 Key Manufacturers Essential Thrombocythemia Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Essential Thrombocythemia Drug Product Location Distribution
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.6 New Products and Potential Entrants
3.7 Mergers and Acquisitions, Expansion
4 World Historic Review for Essential Thrombocythemia Drug by Geographic Region
4.1 World Historic Essential Thrombocythemia Drug Market Size by Geographic Region (2018-2023)
4.2 World Historic Essential Thrombocythemia Drug Market Size by Country/Region (2018-2023)
4.3 Americas Essential Thrombocythemia Drug Sales Growth
4.4 APAC Essential Thrombocythemia Drug Sales Growth
4.5 Europe Essential Thrombocythemia Drug Sales Growth
4.6 Middle East and Africa Essential Thrombocythemia Drug Sales Growth
Get a Sample Copy of the Essential Thrombocythemia Drug Market Report 2023
5 Americas
5.1 Americas Essential Thrombocythemia Drug Sales by Country
5.2 Americas Essential Thrombocythemia Drug Sales by Type
5.3 Americas Essential Thrombocythemia Drug Sales by Channel
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East and Africa
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
10 Manufacturing Cost Structure Analysis
10.2 Manufacturing Cost Structure Analysis of Essential Thrombocythemia Drug
10.4 Industry Chain Structure of Essential Thrombocythemia Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.2 Essential Thrombocythemia Drug Distributors
11.3 Essential Thrombocythemia Drug Customer
12 World Forecast Review for Essential Thrombocythemia Drug by Geographic Region
12.1 Global Essential Thrombocythemia Drug Market Size Forecast by Region
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East and Africa Forecast by Country
12.6 Global Essential Thrombocythemia Drug Forecast by Type
12.7 Global Essential Thrombocythemia Drug Forecast by Channel
13 Key Players Analysis
14 Research Findings and Conclusion
For Detailed TOC - https://www.Absolutereports.Com/TOC/22806938#TOC
Contact Us:
Absolute Reports
Phone: US +1 424 253 0807
UK +44 203 239 8187
Email: [email protected]
Web: https://www.Absolutereports.Com
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit 2023 to 2029 Essential Thrombocythemia Drug Market Report by Product Type & End Users
COMTEX_427702858/2598/2023-03-28T01:17:25
Is there a problem with this press release? Contact the source provider Comtex at [email protected]. You can also contact MarketWatch Customer Service via our Customer Center.
The MarketWatch News Department was not involved in the creation of this content.
Internal Bleeding: Causes, Treatments, And More
Internal bleeding occurs within your body, such as inside the stomach or the brain. Bleeding internally is often the result of trauma or an injury, but there are rarer causes.
An injury that damages the outside of your body is easy to see. A cut or tear in your skin usually bleeds. You can see what's hurt, and it's easy to pinpoint what caused it.
Internal bleeding isn't as easy to see or diagnose. Less obvious causes can result in internal bleeding, too. These include gastritis, organ damage, or a bleeding disorder.
In some cases, the bleeding may be a sign of a life threatening condition. If you or someone you know suddenly develops the following symptoms, seek immediate medical attention. These could be symptoms of internal bleeding:
You may notice bloody or dark vomit or stool. Occasionally, if the bleeding is behind the internal organs in the abdomen, you may have bruising around your navel or on the sides of your abdomen.
Other cases of internal bleeding can be less severe, but it's still important you see your doctor as soon as you notice symptoms.
Internal bleeding is a symptom of an injury, condition, or disease. You won't have internal bleeding without an underlying reason.
Recognizing the symptoms of internal bleeding can help you and your doctor understand what's bleeding, why it's bleeding, and what conditions could be contributing to the problem.
Internal bleeding in your headThis can cause:
Internal bleeding in your chest or abdomenThis can cause:
Internal bleeding into your muscles or jointsThis can cause:
Other symptomsIt's possible to experience shock in some cases of internal bleeding.
This is especially true if internal bleeding occurs in locations where a substantial amount of blood can be lost, such as your chest, abdomen, or thigh. Shock occurs when there's not enough blood to supply your whole body.
Symptoms of shock include:
The presence of other underlying conditions may help doctors identify if you're losing blood somewhere.
For example,anemia is commonly associated with a slow and chronic internal bleeding. It can cause fatigue, weakness, and shortness of breath.
Some people with internal bleeding will also have low blood pressure because of the constant blood loss. This is known as orthostatic hypotension. Common symptoms include feeling dizzy or light-headed when you stand.
Sometimes, identifying what's causing internal bleeding can be simple. If you've been involved in an accident or had a recent injury, the bleeding is likely the result of that event.
Also, diagnosing the cause may be easier if you have a condition that can lead to internal bleeding, such as gastritis.
However, not every case of internal bleeding is so clear-cut. Finding the source of internal bleeding may take some time and require a thorough physical examination.
General causesThese can include:
These can include:
No matter the cause, it's important that you get medical attention. Minor internal bleeding can quickly become more serious if the cause isn't identified and treated quickly.
Diagnosing an internal bleed usually requires medical tests, a physical exam, and a thorough review of your medical history. Your doctor may use lab tests and imaging tools to both identify the cause of your internal bleeding and measure the severity.
For injuries, an imaging test may be all that's necessary. An X-ray shows an image of your bones. A CT scan is an advanced X-ray that can see bones, tissues, and blood vessels. Angiography is an imaging test that can carefully examine individual blood vessels.
If the cause of the bleeding isn't easily determined, your doctor may order several medical tests to help identify what's bleeding and why.
The first goal of treatment is to find the source of the bleeding and stop it. Some bleeding can be minor and may stop on its own. Other cases are more severe and may require more in-depth measures, including surgery.
When your doctor prescribes a treatment for internal bleeding, they'll likely consider:
In mild cases of internal bleeding, treatment typically involves rest and symptom control.
Rest gives your body time to heal while it reabsorbs the blood and the inflammation decreases. A few additional treatment techniques may be necessary for slow bleeds once the cause is identified and treated.
However, some causes of internal bleeding need greater treatment. Surgery may be necessary to stop the bleeding and clean out any pooled blood. The type of surgery you need depends on how severe the bleeding is, where the bleeding is, and your overall health.
After the bleeding stops, treatment will focus on repairing any damage and stabilizing your body.
Depending on the severity, untreated internal bleeding can lead to organ failure, coma, and in some cases death. Even with treatment, severe internal bleeding can result in death.
It's very important to identify and treat internal bleeding early in order to avoid any complications.
It's important to find and treat the cause and risk factors that may lead to internal bleeding. Without quick treatment, you may experience lasting effects.
For example, bleeding in the brain may cause a stroke or long-term brain damage. You may need physical, occupational, and speech therapy to relearn certain behaviors and activities. These therapies may also help prevent future tears or blood vessel damage.
If internal bleeding is caught, diagnosed, and treated appropriately, the outlook is positive. Many people can make a full recovery. Additional treatments may be necessary to prevent a future bleed, but few lasting effects will remain.
